Kymera Therapeutics KYMR Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's total current liabilities?
- Kymera Therapeutics (KYMR) reported total current liabilities of $62.64M in Q1 2026.
- How has Kymera Therapeutics's total current liabilities changed year-over-year?
- Kymera Therapeutics's total current liabilities increased by 6.2% year-over-year, from $58.99M to $62.64M.
- What is the long-term trend for Kymera Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's total current liabilities has grown at a -5.5% compound annual growth rate (CAGR), from $110.62M to $83.21M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.